# EMBARK (NCT02319837)

> Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

No report yet. It can be ordered.

- Drugs tested: enzalutamide
- Indication: high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02319837
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Pfizer
- Conditions: Hormone Sensitive Prostate Cancer; Prostate Cancer; Cancer of the Prostate
- Interventions: Enzalutamide; Placebo (No longer applicable in Open Label study period); Leuprolide Open Label
- Enrollment: 1068
- Primary outcome: Metastasis-free Survival (MFS) Compared Between Enzalutamide Plus Leuprolide and Placebo Plus Leuprolide

## Indexed commentary on EMBARK so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=embark-nct02319837